Cargando…

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

Targeting of α(V)β3 and α(V)β5 integrins by cilengitide may reduce growth of solid tumors including head and neck squamous cell carcinoma (HNSCC). Preclinical investigations suggest increased activity of cilengitide in combination with other treatment modalities. The only published trial in HNSCC (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cedra, Susan, Wiegand, Susanne, Kolb, Marlen, Dietz, Andreas, Wichmann, Gunnar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615332/ https://www.ncbi.nlm.nih.gov/pubmed/28872582 http://dx.doi.org/10.3390/cancers9090117

Ejemplares similares

Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Siemert, Julia, et al.
Publicado: (2021)

Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients
por: Wichmann, Gunnar, et al.
Publicado: (2018)

Malignant Vascular Tumors of the Head and Neck—Which Type of Therapy Works Best?
por: Wiegand, Susanne, et al.
Publicado: (2021)

Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment
por: Wiegand, Susanne, et al.
Publicado: (2019)

Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker
por: Berszin, Michael, et al.
Publicado: (2022)

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
por: Vermorken, J B, et al.
Publicado: (2011)

Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome
por: Röhl, Louisa, et al.
Publicado: (2023)

Efficacy of sirolimus in children with lymphatic malformations of the head and neck
por: Wiegand, S., et al.
Publicado: (2022)

Course of Self-Reported Dysphagia, Voice Impairment and Pain in Head and Neck Cancer Survivors
por: Zebralla, Veit, et al.
Publicado: (2021)

Association between malformation type, location and functional deficits in lymphatic malformations of the head and neck in children
por: Wiegand, Susanne, et al.
Publicado: (2023)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
por: Vermorken, J. B., et al.
Publicado: (2014)

Discrimination of Head and Neck Squamous Cell Carcinoma Patients and Healthy Adults by 10-Color Flow Cytometry: Development of a Score Based on Leukocyte Subsets
por: Wichmann, Gunnar, et al.
Publicado: (2019)

Frailty Assessed with FRAIL Scale and G8 Questionnaire Predicts Severe Postoperative Complications in Patients Receiving Major Head and Neck Surgery
por: Kunz, Viktor, et al.
Publicado: (2022)

Dysphagia, voice problems, and pain in head and neck cancer patients
por: Zebralla, Veit, et al.
Publicado: (2021)

In vitro and in vivo drug disposition of cilengitide in animals and human
por: Dolgos, Hugues, et al.
Publicado: (2016)

Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences
por: Dietz, Andreas, et al.
Publicado: (2011)

Obtaining Patient-Reported Outcomes Electronically With “OncoFunction” in Head and Neck Cancer Patients During Aftercare
por: Zebralla, Veit, et al.
Publicado: (2020)

Gene expression profiling of the anti-glioma effect of Cilengitide
por: Onishi, Manabu, et al.
Publicado: (2013)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

High-Risk Human Papillomavirus (HR-HPV) DNA Detection in Mouthwashes for Diagnosis of HPV-Driven Oropharynx Cancer and Its Curative Therapy—A Feasibility Study
por: Loermann, Gera, et al.
Publicado: (2022)

Verification and characterization of an alternative low density lipoprotein receptor-related protein 1 splice variant
por: Kolb, Marlen, et al.
Publicado: (2017)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Laryngeal Preservation Approaches: Considerations for New Selection Criteria Based on the DeLOS-II Trial
por: Dietz, Andreas, et al.
Publicado: (2019)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Screening for distress, related problems and perceived need for psycho-oncological support in head and neck squamous cell carcinoma (HNSCC) patients: a retrospective cohort study
por: Kunz, V., et al.
Publicado: (2021)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_poken3p6rpumq380soejpvlk3a